Early Release – Bjerkandera spp. Pulmonary Infection in Immunocompromised Hosts, Germany – Volume 31, Number 11—November 2025 – Emerging Infectious Diseases journal

Patient 1 was a 32-year-old man who received allogeneic hematopoietic stem cell transplant (HSCT) for relapsed mediastinal T-cell lymphoma (Table). Nine months later, he experienced progressive dyspnea. The patient was on prednisolone (100 mg/d) immunosuppressive therapy and did not receive antifungal drugs. Computed tomography (CT) of the chest showed new ground-glass opacites and nodular consolidations. Culture from bronchoalveolar lavage (BAL) fluid revealed a mold that we identified as Bjerkandera spp. by sequencing the internal transcribed spacer (ITS) 1/2 region in accordance with Clinical and Laboratory Standards Institute guidelines (10). We did not perform susceptibility testing because fungal growth on the testing media was insufficient. Results of Mucorales and Aspergillus-specific PCR from BAL fluid were negative. Serum was negative for galactomannan antigen. We did not perform BAL galactomannan testing. We identified no other potential causes of infectious diseases by culture, PCR, or serology (Table). We initiated empiric antimicrobial therapy with piperacillin/tazobactam for 2 weeks. The fungus was not considered clinically significant; no antifungal treatment was initiated. We intensified immunosuppression on suspicion of lung graft-versus-host disease, but the patient’s condition continued to deteriorate. We started antifungal therapy with posaconazole both as prophylaxis and targeted treatment of the probable IFD. Eight days later, we performed another BAL in which no fungus or other infectious agent was detected. The patient died shortly afterward from respiratory failure. No autopsy was performed.

Figure 1

Figure 1. Chest computed tomography scan from an 82-year-old female patient with acute myeloid leukemia in study of Bjerkanderaspp. pulmonary infection in immunocompromised hosts, Germany. Image depicts nodular infiltrates and…

Patient 2 was an 82-year-old woman who was referred to the University Hospital Cologne with a diagnosis of acute myeloid leukemia 5 months before admission (Table). She had been treated with azacitidine monotherapy, but after allergic transfusion reaction to platelets, her cancer treatment was discontinued. At admission, the patient was experiencing hyperleukocytosis and neutropenia. We initiated cytoreductive treatment with hydroxyurea. A baseline chest CT scan revealed nodular infiltrates and a subpleural cavitary lesion, suggestive of fungal pneumonia (Figure 1). Of note, the patient had not received any antifungal prophylaxis other than trimethoprim/sulfamethoxazole. Bronchoscopy demonstrated purulent secretions. Results of galactomannan testing of BAL fluid were positive; culture yielded a preliminary phenotypic identification of Geotrichum spp. All other diagnostic work-up results were unremarkable (Table). Given the clinical significance of the mold identification, we pursued further species-level analysis. ITS sequencing identified the organism as either B. adusta or B. fumosa (10). Aspergillus PCR was negative. We could not perform antifungal susceptibility testing because of insufficient fungal growth. We initiated voriconazole therapy but switched to isavuconazole because the patient experienced visual disturbances. Follow-up chest CT scans at 2 and 5 weeks showed stable disease. After 5 weeks of antifungal therapy, we discontinued treatment and initiated posaconazole as secondary prophylaxis. No additional follow-up visits occurred.

Figure 2

Figure 2. Chest computed tomography scan of a 4-year-old male patient with acute myeloid leukemia in study of Bjerkanderaspp. pulmonary infection in immunocompromised hosts, Germany. The patient experienced fever unresponsive…

Patient 3 was a 4-year-old boy with newly diagnosed acute myeloid leukemia who initially received cytarabine-based induction chemotherapy (Table). He experienced seizures secondary to cerebral hemorrhage, requiring mechanical ventilation. After successful extubation, we resumed chemotherapy using a high-dose cytarabine and mitoxantrone regimen. He received micafungin (4 mg/kg 2×/wk) as antifungal prophylaxis. Subsequently, he experienced febrile neutropenia (temperature 39.2°C/102.6°F) that was unresponsive to empiric broad-spectrum antimicrobial treatment with meropenem and vancomycin, raising suspicion for IFD. We initiated voriconazole. Serum galactomannan test results were negative. A chest CT scan demonstrated nodular infiltrates and a new cavitary lesion radiographically consistent with a mold infection (Figure 2, panel A). We switched antifungal therapy to liposomal amphotericin B (L-AmB). Fungal culture from a tracheal aspirate yielded a mold with sterile mycelium, which we identified via ITS sequencing as B. adusta or B. fumosa (10). Other diagnostic assessments yielded no findings (Table). After 2 weeks of L-AmB therapy, the patient experienced hypokalemia, requiring a switch back to voriconazole. A follow-up CT scan performed 3 weeks later demonstrated a radiographic response to treatment (Figure 2, panel B). No further imaging was done. The patient continued voriconazole therapy for a total of 4 months.

We described 3 cases with probable invasive lung infections caused by Bjerkandera spp. in 2 adults and 1 pediatric patient with hematologic malignancies. We identified no other fungal pathogens or alternative infectious agents by culture, PCR, or serology. All cases met criteria for probable invasive pulmonary mold infection (11). Multidisciplinary teams discussed the possibility of contamination and likelihood of invasive disease by Bjerkandera spp. and concluded that the identification of Bjerkandera spp. was consistent with an IFD in each case, warranting antifungal treatment.

Figure 3

Figure 3. Images of Bjerkandera spp. formations from study of Bjerkandera spp. pulmonary infection in immunocompromised hosts, Germany. Slides are of lactophenol preparation (original magnification ×1,000). Bjerkandera…

We identified the fungus in all 3 cases by sequencing techniques, underlining the importance of molecular approaches in the evaluation of rare fungal infections. In patient 2, B. adusta was preliminary identified as Geotrichum spp. based on phenotypic appearance. Geotrichum spp. are environmental fungi that cause opportunistic infections in at-risk populations (12). Both fungi share phenotypic features such as whitish, fluffy to woolly colony morphology and wide-branching septate hyphae with formation of arthroconidia and only occasional formation of chlamydospores (Figure 3) (6,13). Therefore, reliable identification in filamentous basidiomycetes requires additional techniques such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and sequencing methods. Sequence analysis of the ITS ribosomal DNA has better accuracy for species identification; however, for rare fungi, reference data may be incomplete or unavailable for both methods (14).

Guidance for clinical management of emerging IFD remains limited because IFD is rare and clinical manifestations vary. Susceptibility test results of 14 B. adusta isolates included high MIC for fluconazole and flucytosine and low MIC for AmB and newer triazoles (15). Clinical improvement with itraconazole treatment has been described (14) in cases with chronic cough associated with Bjerkandera spp., consistent with in vitro susceptibility findings. One reported case-patient with invasive rhinosinusitis caused by Bjerkandera was treated sequentially with L-AmB, posaconazole, and voriconazole, leading to clinical recovery (9). We used newer triazoles and L-AmB for treatment with variable responses. The lack of comprehensive susceptibility testing and outcome data limits definitive treatment recommendations for suspected IFD caused by Bjerkandera spp. Describing an unusual pathogen carries a risk for error. We were unable to demonstrate fungal growth in independent respiratory specimens or to obtain histologic proof of invasive growth from lung biopsy.

Our findings suggest that Bjerkandera spp. is a human pathogen causing invasive fungal pneumonia or other pulmonary infection in persons at risk, including the immunocompromised. Evaluating the clinical relevance of such infections must consider the degree of immunosuppression and the patient’s future treatment plans.